PGX-YBG/FibrosisIn October Gilles said that PGX-YBG/Fibrosis only required a short toxicology study and that they were moving ahead with planning a human clinical trail regardless. While it wasn't a full 'go' decision for a clinical trial it wasn't a 'no-go' decision. Since then preclinical PGX-YBG/Fibrosis results were sent to a leading industry journal for peer-review and potential publishing. CZO has also closed the AEZS merger and the human resources and capital could support a clinical trial 'go' decision. Maybe we hear a clinical trial 'go' decision soon with the publishing of preclinical results in a leading journal. Dr. Martin Kolb previously said that if preclinical results are replicated in humans it could profoundly change the treatment landscape. He helped bring Avalyn's inhaled fibrosis drug to trials with Dr. Ask and Avalyn raised C$80 million to bring its drug to a Phase I trial. COVID fibrosis wasn't a problem then and PGX-YBG can also be used as a delivery platform to deliver other drugs. PGX-YBG could also treat fibrosis outside the lungs as Dr. Ask has mentioned.
April 2024 news release:
- Announced on May 23, 2023 the completion of CHRP collaboration with McMaster University with encouraging results evaluating PGX-processed YBG for interstitial lung diseases. These results triggered presentations at International scientific conferences confirming that PGX-YBG is suitable for inhalation and can act through a newly discovered mechanism of action through specific binding on white blood cells (macrophages) involved in the inflammation and fibrotic process. A comprehensive scientific article was recently submitted to the Biomaterials scientific journal.